BioSpace News Archive

NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, announces first clinical data from the ongoing Phase 1/2 study of NVG-111, a novel ROR1 targeting bispecific antibody T cell engager, in patients with relapsed and refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Viemed Healthcare, Inc. (the “ Company ” or “ Viemed ”) (NASDAQ:VMD and TSX:VMD.TO), a home medical equipment supplier and the nation’s largest independent provider of ventilation that provides post-acute respiratory care services, announced that it will host a webcast investor presentation on Thursday, June 2nd , 2022 at 2:00 PM ET.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights to guide and clarify cancer treatment and risk assessment.

Biomea Fusion, Inc. (Nasdaq: BMEA), today announced it will present new data at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating BMF-219’s activity in ex vivo preclinical models of CLL.

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and year ended March 31, 2022.

Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, will present updates at the 2022 annual meeting of the American Society for Clinical Oncology in Chicago June 3-7 describing multiple applications for its next-generation liquid biopsy platform.

New findings demonstrate the clinical efficacy of AI-powered tissue analysis as a guide in cancer treatment, according to medical AI provider Lunit.

Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that its seven clinical abstracts selected by the 2022 American Society of Clinical Oncology Annual Meeting, of which six were selected for presentations and one was selected for publication-only, have been published on the ASCO’s website.

Taiwanese biotech outfit AcadeMab has broken new ground in the development of COVID immunotherapies through the development of a potentially life-saving monoclonal antibodies for COVID-19 patients using single B cell technology, shows the best neutralization ability in both Omicron variants BA.1 and BA.2 respectively.